Skip to main content
SpringerLink
Log in

Disease Burden of Overactive Bladder

Quality-of-Life Data Assessed Using ICI-Recommended Instruments

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Overactive bladder (OAB) is characterised by the storage symptoms of urgency, with or without urge incontinence, and usually with urinary frequency and nocturia. OAB is a common condition that affects people of all ages within society. It has an estimated prevalence of 16% and is known to adversely affect quality of life (QOL).

Assessment of the QOL of patients is important to understanding both the burden of disease and improvement after treatment. In clinical practice, the physician’s assessment of the disease burden of OAB has been shown to be inaccurate and non-reproducible. Psychometrically robust self-completion questionnaires provide a valid, reproducible and rapid assessment of patient-reported disease impact that can elicit the impact of symptoms, and they are also useful for the evaluation of the efficacy of an intervention.

Many different questionnaires have been developed to assess the QOL impact of OAB. Generic instruments measure very broad aspects of health and are suitable for a wide range of patient groups and general population screening. They can be applied to patients with any medical condition and provide a measure of morbidity but are less sensitive to clinically relevant change in conditions such as OAB. Condition-specific questionnaires offer greater sensitivity and responsiveness to change in the assessment of QOL of specific patient groups. Single-item global assessment questionnaires are useful in conditions such as OAB that have multiple and varied symptoms, and reflect an individual’s needs, concerns and values. Patient-derived outcome measures are used in real-world clinical practice, clinical trials, health economic research and healthcare planning.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Khoury S, et al. Incontinence: volume 1. Basics and evaluation. Paris: Health Publications Ltd, 2005

    Google Scholar 

  2. Kelleher CJ, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95 (1): 81–85

    Article  PubMed  Google Scholar 

  3. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 May; 20 (6): 327–336

    PubMed  CAS  Google Scholar 

  4. Milson I, Abrams P, Cardozo L, et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87 (9): 760–766

    Article  Google Scholar 

  5. Sand PK, Hill RC, Ostergard DR. Incontinence history as a predictor of detrusor stability. Obstet Gynecol 1988; 71 (2): 257–260

    PubMed  CAS  Google Scholar 

  6. Wyman JF, Choi SC, Harkins SW, et al. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynaecol 1988; 71: 812–817

    CAS  Google Scholar 

  7. Larrson G, Victor A. Micturition patterns in a healthy female population, studied with a frequency/volume chart. Scand J Urol Nephrol Suppl 1998; 114: 53–57

    Google Scholar 

  8. Barnick C. Frequency/volume charts. In: Cardozo L, editor. Urogynecology: the Kings approach. New York: Churchill Livingstone, 1997

    Google Scholar 

  9. Cardozo L, Staskin D. Textbook of female urology and urogynaecology. Oxford: Isis Medical Media, 2001

    Google Scholar 

  10. Lose G, Jorgensen L, Thunedborg P. 24-hour home pad weighing test versus 1-hour ward test in the assessment of mild stress incontinence. Acta Obstet Gynecol Scand 1989; 68: 211–215

    Article  PubMed  CAS  Google Scholar 

  11. Miller JM, Ashton-Miller JA, DeLancey JOL. The quantitative paper towel test for measuring stress related urine loss [abstract]. Proc Am Urogynecologic Soc, 18th Annual meeting. Tuscon: American Urogynecologic Society, 1997 Sep 25-28: 44

    Google Scholar 

  12. Cardozo L, Dixon A. Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 2005; 173: 1214–1218

    Article  PubMed  Google Scholar 

  13. Chapple C, Artibani W, Cardozo L, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95: 325–340

    Google Scholar 

  14. Rodriguez LV, Blander DS, Dorey F, et al. Discrepancy in patient and physician perception of patient’s quality of life related to urinary symptoms. Urology 2003; 62 (1): 49–53

    Article  PubMed  Google Scholar 

  15. Neumann PJ, Araki SS, Gutterman EM. The use of proxy respondents in studies of older adults: lessons, challenges, and opportunities. J Am Geriatr Soc 2000 Dec; 48 (12): 1646–1654

    PubMed  CAS  Google Scholar 

  16. Ware JE, Shebourne CD. The MOS 36-item- short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992 Jun; 30 (6): 473–483

    Article  PubMed  Google Scholar 

  17. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. BJOG 1997; 104 (12): 1374–1379

    Article  CAS  Google Scholar 

  18. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OABq. Qual Life Res 2002; 11 (6): 563–574

    Article  PubMed  CAS  Google Scholar 

  19. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–172

    Article  PubMed  CAS  Google Scholar 

  20. Avery K, Donovan J, Peters TJ, et al. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 2004; 23 (4): 322–330

    Article  PubMed  Google Scholar 

  21. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 Jun; 49 (6): 1079–1086

    Article  PubMed  Google Scholar 

  22. Camilleri-Brennan J, Ruta DA, Steele J. Patient generated index: new instrument for measuring quality of life in patients with rectal cancer. World J Surg 2002; 26 (11): 1354–1359

    Article  PubMed  Google Scholar 

  23. The EuroQoL Group. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (3): 199–208

    Article  Google Scholar 

  24. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993 Apr 15; 118 (8): 622–629

    PubMed  CAS  Google Scholar 

  25. Malone-Lee J, Shaffu B, Anand C, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001 May; 165 (5): 1452–1456

    Article  PubMed  CAS  Google Scholar 

  26. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50 (6A Suppl.): 90

    Article  PubMed  CAS  Google Scholar 

  27. Malone-Lee J, Eriksson M, Olofsson S, et al. The comparative tolerability and efficacy of tolterodine 2mg bid versus oxybutynin 2.5/5mg bid in the treatment of the overactive bladder. Conference of the International Continence Society; 1998 Apr 2–3; Cambridge, UK

    Google Scholar 

  28. Hunt SM, McKenna SP, McEwen J, et al. A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 1980 Dec; 34 (4): 281–286

    Article  PubMed  CAS  Google Scholar 

  29. Grimby A, Milstrom I, Molander U, et al. The influence of urinary incontinence on the quality of life of women of elderly women. Age Ageing 1993; 22 (2): 82–89

    Article  PubMed  CAS  Google Scholar 

  30. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981 Aug; 19 (8): 787–805

    Article  PubMed  CAS  Google Scholar 

  31. Hunskaar S, Vinsnes A. The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc 1991 Apr; 39 (4): 378–382

    PubMed  CAS  Google Scholar 

  32. Oh SJ, Ku JH. Is a generic quality of life instrument helpful for evaluating women with urinary incontinence? Qual Life Res 2006 Apr; 15 (3): 493–501

    Article  PubMed  Google Scholar 

  33. Hannestad Y, Rortveit G, Sandvik H, et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT Study. J Clin Epidemiol 2000; 53 (11): 1150–1157

    Article  PubMed  CAS  Google Scholar 

  34. Kelleher CJ, Kreder KJ, Pleil AM, et al. Long term health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Manag Care 2002 Dec; 8 (19 Suppl.): S616–S630

    PubMed  Google Scholar 

  35. Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 1999 Apr; 83 (6): 583–590

    Article  PubMed  CAS  Google Scholar 

  36. Chapple C, Kelleher C, Perrault L. Darifenacin an M3 selective receptor antagonist improves quality of life on patients with overactive bladder. Poster presented at World Health Organization’s 3rd International Consultation on Incontinence; 2004 Jun 26–29; Monaco

    Google Scholar 

  37. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase 3 studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005 May; 95 (7): 993–1001

    Article  PubMed  CAS  Google Scholar 

  38. Reese PR, Pleil AM, Okano GJ, et al. Multinational study of reliability and validity of the King’s Health Questionnaire in patients with overactive bladder. Qual Life Res 2003 Jun; 12 (4): 427–442

    Article  PubMed  Google Scholar 

  39. Coyne K, Matza L, MEDTAP. How responsive is the overactive bladder questionnaire (OAB-q) to changes in urgency episodes, micturitions and incontinence? [abstract; online]. Available from URL: www.icsoffice.org/publications 2002 [Accessed 2006 Jan 8]

  40. Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res 1994 Oct; 3 (5): 291–306

    Article  PubMed  CAS  Google Scholar 

  41. Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-a toxin on patients with severe urge urinary incontinence. J Urol 2004 Dec; 172 (6 Pt 1): 2316–2320

    Article  PubMed  CAS  Google Scholar 

  42. Wagner TH, Patrick DL, Bavendam TG, et al. Quality of life of persons with urinary incontinence; development of a new measure. Urology 1996; 47 (1): 67–71

    Article  PubMed  CAS  Google Scholar 

  43. Taylor SE, Brown JD. Positive illusions and well-being revisited: separating fact from fiction. Psychol Bull 1994 Jul; 116 (1): 21–27

    Article  PubMed  CAS  Google Scholar 

  44. Berghmans L, Nieman F, van Waalwijk van Doorn E, et al. Effects of physiotherapy, using the Dutch adapted I-QOL in women with urge incontinence [abstract]. Neurourol Urodyn 2001; 20: 509–510

    Google Scholar 

  45. Jackson S, Donovan J, Brookes S, et al. The Bristol female lower urinary tract symptoms questionnaire: development and psychometric testing. Br J Urol 1996 Jun; 77 (6): 805–812

    Article  PubMed  CAS  Google Scholar 

  46. Teleman P, Lidfeldt J, Nerbrand C, et al. Lower urinary tract symptoms in middle-aged women: prevalence and attitude towards mild urinary incontinence. A community-based population study. Acta Obstet Gynecol Scand 2005 Nov; 84 (11): 1108–1112

    Article  PubMed  Google Scholar 

  47. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580–586

    Article  PubMed  CAS  Google Scholar 

  48. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464–470

    Article  PubMed  CAS  Google Scholar 

  49. Freeman R, Hill S, Millard R, et al. Tolterodine study group: reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 2003; 102 (3): 605–611

    Article  PubMed  Google Scholar 

  50. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int 2005 Mar; 95 (4): 591–596

    Article  PubMed  Google Scholar 

  51. Kelleher CJ, Pleil AM, Reese PR, et al. How much is enough and who says so? The case of the King’s Health Questionnaire and overactive bladder. BJOG 2004 Jun; 111 (6): 605–612

    Article  PubMed  Google Scholar 

  52. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003 Apr 19; 326 (7394): 841–844

    Article  PubMed  CAS  Google Scholar 

  53. Lai HH, Boone TB, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol 2002; 4 Suppl. 4: S28–S37

    PubMed  Google Scholar 

  54. Jarernsiripornkul N, Krska J, Capps PAG, et al. Patient reporting of potential adverse drug reactions: a methodological study. BR J Clin Pharmacol 2002; 53 (3): 318–325

    Article  PubMed  CAS  Google Scholar 

  55. Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Uro 2005; 47: 376–384

    Article  CAS  Google Scholar 

  56. Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 2000 Jun; 163 (6): 1849–1854

    Article  PubMed  CAS  Google Scholar 

  57. Nabi G, Yong SM, Ong E, et al. Is orthoptic bladder replacement the new gold standard? Evidence from a systematic review. J Urol 2005 Jul; 174 (1): 21–28

    Article  PubMed  CAS  Google Scholar 

  58. Hautmann RE. Urinary diversion: ileal conduit to neobladder. J Urol 2003 Mar; 169 (3): 834–842

    Article  PubMed  Google Scholar 

  59. van Voskuilen AC, Oerlemans DJ, Weil EH, et al. Long-term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study. Eur Urol 2006 Feb; 49 (2): 366–372

    Article  PubMed  Google Scholar 

  60. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006 July; 176 (1): 177–185

    Article  PubMed  CAS  Google Scholar 

  61. Rajkumar GN, Small DR, Mustafa AW, et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005 Oct; 96 (6): 848–852

    Article  PubMed  CAS  Google Scholar 

  62. Chapple C, Khullar V. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48 (1): 5–26

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review.

Drs Basra and Kelleher have applied to Pfizer for grants this year. Dr Kelleher has also acted as a consultant to Astellas Pharma, Novartis, Pfizer, Avera and UCB Pharma; has received lecture fees from Astellas Pharma, Novartis, Pfizer and UCB Pharma; and has previously received a grant from Pfizer.

The authors would like to acknowledge Dr Eduard Cortes for his contribution to this work.

Author information

Authors and Affiliations

  1. Guys & St Thomas’ NHS Foundation Trust, 8 Devonshire Place, London, W1G 6HP, UK

    Ramandeep Basra &  Con Kelleher

Authors
  1. Ramandeep Basra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Con Kelleher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Con Kelleher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basra, R., Kelleher, C. Disease Burden of Overactive Bladder. Pharmacoeconomics 25, 129–142 (2007). https://doi.org/10.2165/00019053-200725020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200725020-00005

Keywords

Search

Navigation